£8 million funding for new start-up TopiVert
TopiVert has licensed NSKI (narrow spectrum kinase inhibitor) related intellectual property from RespiVert Ltd., a former Imperial Innovations portfolio company acquired by Janssen Biotech, Inc. (formerly known as Centocor Ortho Biotech Inc.) in 2010, for TopiVert’s exclusive use in discovering and developing NSKIs for inflammatory diseases of the eye and gut. Both participants in this funding round were also investors in RespiVert.
TopiVert will enter into an exclusive drug discovery collaboration with RespiVert aimed at identifying new NSKIs. TopiVert will receive exclusive rights to select and develop resulting NSKIs for the treatment of inflammatory diseases of the eye and gut, such as uveitis and inflammatory bowel disease, while RespiVert will receive exclusive rights to select and develop resulting NSKIs for the treatment of other indications, such as inflammatory diseases of the lungs.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.